Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

P. Delmar · SciRah

Researcher profile · Semantic Scholar

P. Delmar

Share profile

P. Delmar — researcher profile on SciRah

h-index: 27
Works: 107
Citations: 3,429

Most-cited papers

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
S. Ostrowitzki, R. Lasser, E. Dorflinger, P. Scheltens +13 more
2017Alzheimer's Research & Therapy492 citations Open access
Semantic Scholar
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.
E. Van Cutsem, S. de Haas, Yoon-Koo Kang, A. Ohtsu +7 more
2012Journal of Clinical Oncology476 citations
Semantic Scholar
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
S. Salloway, M. Farlow, E. McDade, D. Clifford +61 more
2021Nature Medicine298 citations Open access
Semantic Scholar
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.
D. Lambrechts, B. Claes, P. Delmar, J. Reumers +10 more
2012The Lancet Oncology190 citations
Semantic Scholar
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis
G. Klein, P. Delmar, N. Voyle, S. Rehal +10 more
2019Alzheimer's Research & Therapy178 citations Open access
Semantic Scholar
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
D. Miles, S. D. de Haas, L. Dirix, G. Romieu +7 more
2013British Journal of Cancer168 citations Open access
Semantic Scholar
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations
B. Klughammer, W. Brugger, F. Cappuzzo, T. Ciuleanu +9 more
2016Journal of Thoracic Oncology98 citations Open access
Semantic Scholar
Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer’s Disease
C. Lansdall, F. Mcdougall, L. Butler, P. Delmar +6 more
2022The journal of prevention of Alzheimer's disease85 citations Open access
Semantic Scholar
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL.
N. Dimier, P. Delmar, Carol Ward, R. Morariu-Zamfir +11 more
2018Blood79 citations Open access
Semantic Scholar
Phase I Trial of Anti-Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration.
U. Chakravarthy, C. Bailey, David M. Brown, P. Campochiaro +13 more
2017Ophthalmology Retina78 citations Open access
Semantic Scholar
A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer’s disease
Guo-Qiao Wang, Scott Berry, C. Xiong, Jason J. Hassenstab +6 more
2018Statistics in Medicine58 citations Open access
Semantic Scholar
A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015)
T. Mok, V. Gorbunova, E. Juhász, B. Szima +8 more
2014Journal of Thoracic Oncology55 citations Open access
Semantic Scholar
Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib.
J. Davies, M. Martinec, P. Delmar, M. Coudert +4 more
2018Journal of Comparative Effectiveness Research54 citations Open access
Semantic Scholar
Sembragiline in Moderate Alzheimer’s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)
S. Nave, R. Doody, M. Boada, T. Grimmer +17 more
2017Journal of Alzheimer's Disease54 citations Open access
Semantic Scholar
Psychometric Properties of the Clinical Dementia Rating — Sum of Boxes and other Cognitive and Functional Outcomes in a Prodromal Alzheimer’s Disease Population
F. Mcdougall, C. Edgar, M. Mertes, P. Delmar +5 more
2020The journal of prevention of Alzheimer's disease53 citations Open access
Semantic Scholar
Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab
G. Klein, P. Delmar, G. Kerchner, C. Hofmann +6 more
2020The journal of prevention of Alzheimer's disease52 citations Open access
Semantic Scholar
Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy
S. de Haas, P. Delmar, A. Bansal, M. Moisse +8 more
2014Angiogenesis47 citations Open access
Semantic Scholar
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer
E. Tan, R. Ramlau, A. Płużańska, H. Kuo +14 more
2010Annals of Oncology44 citations Open access
Semantic Scholar
A statistician's perspective on biomarkers in drug development
Martin Jenkins, A. Flynn, T. Smart, C. Harbron +6 more
2011Pharmaceutical statistics41 citations
Semantic Scholar
804 ORAL Evaluation of Plasma VEGFA as a Potential Predictive Pan-tumour Biomarker for Bevacizumab
G. Jayson, S. D. de Haas, P. Delmar, D. Miles +6 more
201137 citations
Semantic Scholar
803 ORAL Analysis of Blood Plasma Factors in the AVITA Phase III Randomized Study of Bevacizumab (bev) With Gemcitabine-Erlotinib (GE) in Patients (pts) With Metastatic Pancreatic Cancer (mPC)
E. Van Cutsem, G. Jayson, C. Dive, P. Dilba +4 more
201133 citations
Semantic Scholar
Genetic markers of bevacizumab-induced hypertension
D. Lambrechts, M. Moisse, P. Delmar, D. Miles +8 more
2014Angiogenesis32 citations Open access
Semantic Scholar
Standard and reference‐based conditional mean imputation
M. Wolbers, Alessandro Noci, P. Delmar, Craig Gower-Page +2 more
2021Pharmaceutical statistics30 citations Open access
Semantic Scholar
Abstract P2-16-04: Plasma Biomarker Analyses in the AVADO Phase III Randomized Study of First-Line Bevacizumab + Docetaxel in Patients with Human Epidermal Growth Factor Receptor (HER) 2-Negative Metastatic Breast Cancer
D. Miles, S. D. de Haas, L. Dirix, A. Chan +5 more
201028 citations
Semantic Scholar
Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma.
J. Delord, J. Tabernero, R. García-Carbonero, A. Cervantes +13 more
2014European Journal of Cancer25 citations
Semantic Scholar
Use of a historical control group in a noninferiority trial assessing a new antibacterial treatment: A case study and discussion of practical implementation aspects
D. Dejardin, P. Delmar, Charles Warne, Katie Patel +2 more
2018Pharmaceutical statistics23 citations
Semantic Scholar
Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's disease
Guo-Qiao Wang, Lei Liu, Yan Li, A. Aschenbrenner +6 more
2022Alzheimer's & Dementia21 citations Open access
Semantic Scholar
O1‐09‐02: THE EFFECT OF LOW DOSES OF GANTENERUMAB ON AMYLOID AND TAU BIOMARKERS IN CEREBROSPINAL FLUID (CSF) IN THE MARGUERITE ROAD STUDY
N. Voyle, D. Abi‐Saab, G. Klein, C. Hofmann +7 more
201821 citations
Semantic Scholar
O1‐09‐04: UPDATE ON THE SAFETY AND TOLERABILITY OF GANTENERUMAB IN THE ONGOING OPEN‐LABEL EXTENSION (OLE) OF THE MARGUERITE ROAD STUDY IN PATIENTS WITH MILD ALZHEIMER'S DISEASE (AD) AFTER APPROXIMATELY TWO YEARS OF STUDY DURATION
D. Abi‐Saab, M. Andjelkovic, N. Pross, P. Delmar +7 more
201820 citations
Semantic Scholar
Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients
W. Berkofsky-Fessler, T. Q. Nguyen, P. Delmar, J. Molnos +10 more
2009Molecular Cancer Therapeutics20 citations Open access
Semantic Scholar
O1‐09‐05: UPDATE ON THE SAFETY AND TOLERABILITY OF GANTENERUMAB IN THE ONGOING OPEN‐LABEL EXTENSION OF THE SCARLET ROAD STUDY IN PATIENTS WITH PRODROMAL ALZHEIMER'S DISEASE AFTER APPROXIMATELY 2 YEARS OF STUDY DURATION
M. Andjelkovic, D. Abi‐Saab, P. Delmar, N. Pross +7 more
201819 citations
Semantic Scholar
Higher Dose Gantenerumab leads to Significant Reduction in Amyloid Plaque Burden -Results for the Marguerite and Scarlet Road Open Label Extension Studies (S2.005)
G. Klein, P. Delmar, C. Hofmann, Mirjana Adjelkovic +5 more
2018Neurology19 citations
Semantic Scholar
PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non–Small-Cell Lung Cancer
D. Soulières, F. Hirsch, F. Shepherd, W. Bordogna +3 more
2015Journal of Thoracic Oncology17 citations Open access
Semantic Scholar
An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma
S. Temam, J. Spicer, F. Farzaneh, J. Soria +16 more
2017Annals of Oncology16 citations Open access
Semantic Scholar
Changes in transcriptome after in vivo exposure to ionising radiation reveal a highly specialised liver response
A. Pawlik, P. Delmar, S. Bosse, L. Sainz +4 more
2009International Journal of Radiation Biology16 citations
Semantic Scholar
Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients
J. Davies, M. Martinec, M. Coudert, P. Delmar +1 more
2018Current Medical Research and Opinion15 citations
Semantic Scholar
1414 POSTER Single Nucleotide Polymorphism Analysis and Outcome in Advanced-stage Cancer Patients Treated With Bevacizumab
D. Lambrechts, P. Delmar, D. Miles, N. Leighl +6 more
201114 citations
Semantic Scholar
Comparing ARIA‐E severity scales and effects of treatment management thresholds
G. Klein, M. A. Scelsi, J. Barakos, J. Fiebach +8 more
2022Alzheimer's & Dementia13 citations Open access
Semantic Scholar
Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis
F. Hourcade‐Potelleret, S. Laporte, V. Lehnert, P. Delmar +4 more
2015Heart13 citations
Semantic Scholar
9172 Analysis of biomarkers (BMs) in the AVAiL phase III randomised study of first-line Bevacizumab (Bv) with cisplatin-gemcitabine (CG) in patients (pts) with non-small cell lung cancer (NSCLC)
N. Leighl, M. Reck, S. D. de Haas, S. Evers +3 more
200913 citations
Semantic Scholar
16LBA VEGFR-1 polymorphisms as potential predictors of clinical outcome in bevacizumab-treated patients with metastatic pancreatic cancer
D. Lambrechts, P. Delmar, I. Buysschaert, B. Claes +6 more
200913 citations
Semantic Scholar
In silico exploration of amyloid‐related imaging abnormalities in the gantenerumab open‐label extension trials using a semi‐mechanistic model
R. Aldea, H. Grimm, R. Gieschke, C. Hofmann +8 more
2022Alzheimer's & Dementia12 citations Open access
Semantic Scholar
[P1–045]: THE EFFECT OF 6 MONTHS’ DOSING ON THE RATE OF AMYLOID‐RELATED IMAGING ABNORMALITIES (ARIA) IN THE MARGUERITE ROAD STUDY
D. Abi‐Saab, M. Andjelkovic, P. Delmar, N. Voyle +2 more
201711 citations Open access
Semantic Scholar
Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
Guo-Qiao Wang, Yan Li, C. Xiong, E. McDade +26 more
2022Alzheimer's & Dementia10 citations Open access
Semantic Scholar
Classification, Prediction, and Concordance of Cognitive and Functional Progression in Patients with Mild Cognitive Impairment in the United States: A Latent Class Analysis
J. Mouchet, K. Betts, M. Georgieva, R. Ionescu-Ittu +7 more
2021Journal of Alzheimer's Disease10 citations Open access
Semantic Scholar
Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
S. Ostrowitzki, R. Lasser, E. Dorflinger, P. Scheltens +13 more
2018Alzheimer's Research & Therapy9 citations Open access
Semantic Scholar
Evaluating Digital Twins for Alzheimer’s Disease using Data from a Completed Phase 2 Clinical Trial
Jonathan R. Walsh, S. Roumpanis, D. Bertolini, P. Delmar
2022Alzheimer's & Dementia8 citations
Semantic Scholar
9003 ORAL Biomarker Analysis in BO21015, a Phase II Randomised Study of First-line Bevacizumab (BEV) Combined With Carboplatin-gemcitabine (CG) or Carboplatin-paclitaxel (CP) in Patients (pts) With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC)
T. Mok, V. Gorbunova, E. Juhász, B. Szima +6 more
20118 citations
Semantic Scholar
Investigation of predictive biomarkers for R1507, an anti-IGF1R antibody, in patients with advanced non-small cell lung cancer with progression after first-line chemotherapy.
Kai Habben, P. Delmar, C. Brownstein, W. Koehler +5 more
2011Journal of Clinical Oncology8 citations
Semantic Scholar
Graduation study design: Evaluation of once‐weekly subcutaneous administration of gantenerumab on brain amyloid load
F. Boess, Shunsuke Sakaoka, D. Abi‐Saab, Marzia Antonella Scelsi +6 more
2021Alzheimer's & Dementia7 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

G. Klein×11
Invite
G. Klein — researcher profile on SciRah
S. Scherer×11
Invite
S. Scherer — researcher profile on SciRah
R. Doody×11
Invite
R. Doody — researcher profile on SciRah
P. Fontoura×10
Invite
P. Fontoura — researcher profile on SciRah

×9

Invite

C. Hofmann — researcher profile on SciRah

D. Abi‐Saab×9

Invite

D. Abi‐Saab — researcher profile on SciRah

E. Van Cutsem×8

Invite

E. Van Cutsem — researcher profile on SciRah

M. Andjelkovic×7

Invite

M. Andjelkovic — researcher profile on SciRah

Invite

G. Kerchner — researcher profile on SciRah

P. Carmeliet×6

Invite

P. Carmeliet — researcher profile on SciRah

Invite

N. Voyle — researcher profile on SciRah

Invite

D. Miles — researcher profile on SciRah